Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial is about testing GO-203-2c, which is a newly discovered compound that binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in many cancers). By binding to MUC1, GO-203-2c eventually causes tumor cell death in laboratory studies.

This study is being done to:

• Test the safety of GO-203-2c and see what effects (good and bad) it has on you and your cancer

• Find the highest dose of GO-203-2c that can be given without causing bad side effects

• Examine how much GO-203-2c is in the blood at certain times after it is given and how quickly the body gets rid of it

• Observe whether there is any effect of GO-203-2c on the size and activity of cancer in your body

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genus Oncology, LLC

Criteria

Inclusion Criteria:

• Histologically confirmed solid tumors or lymphomas

• Tumor progression observed after receiving standard/approved systemic chemotherapy and/or immunotherapy including monoclonal antibodies, or when there is no approved or effective therapy

• One or more measureable tumors by radiological evaluation

• Karnofsky performance ≥ 70%

• Life expectancy of ≥ 3 months

• Age ≥ 18 years

• Signed, written IRB-approved informed consent

• Negative pregnancy test (if female)

• Adequate liver function:

• Bilirubin less than or equal to 1.5 x upper limit of normal (ULN)

• AST (SGOT), ALT (SGPT) and Alkaline phosphatase less than or equal to 2.5 x ULN (if liver metastases are present, then less than or equal to 5 x ULN is allowed)

• Adequate renal function:

• Serum creatinine within normal limits, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with serum creatinine above institutional ULN.

• Corrected serum calcium ≥ lower limit of the institutional normal range (LLN)

• Serum phosphorus level ≥ LLN

• Adequate hematologic function:

• Absolute Neutrophil Count ≥ 1500 cells/mm3

• Platelet count ≥ 100,000 (cells/mm3)

• Hemoglobin ≥ 9 g/dL

• Urinalysis:

• No clinically significant abnormalities

• Adequate coagulation function:

• PT ≤ 1.25 x ULN

• PTT ≤ 1.25 x ULN

• For men and women of child-producing potential, agreement to use effective contraceptive methods during the study

Exclusion Criteria:

• New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG

• Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy

• Pregnant or nursing women. NOTE: Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.

• Major surgery within 4 weeks prior to Day 1, or not fully recovered by Day 1

• Minor surgery within 2 weeks prior to Day 1, or not fully recovered by Day 1

• Treatment with radiation therapy within 4 weeks prior to Day 1.

• Received systemic chemotherapy or monoclonal antibody or other immunotherapy within 4 weeks prior to Day 1 (exceptions: 6 weeks for nitrosourea, mitomycin C, or any agent with a known treatment effect > 4 weeks' duration), or not fully recovered from any side effects from previous therapy by Day 1

• History of allergic reactions attributed to excipients or chemical products used in the final GO-203-2c drug formulation

• Known infection with HIV, hepatitis B, or hepatitis C.

• Subjects with risk factors for gastrointestinal perforation or pulmonary hemorrhage (e.g. unresected luminal intestinal cancers; abdominal carcinomatosis within 3 months before the first dose of study drug, abdominal fistula, acute diverticulitis, peptic ulcer disease, irritable bowel syndrome, Crohn's disease, pulmonary hemorrhage, hemoptysis, or tuberculosis)

• Currently receiving or having received treatment with any other investigational agent within 4 weeks prior to Day 1, or not fully recovered from toxicities of prior treatment by Day 1

• Serious and/or poorly controlled non-malignant disease (including but not limited to, ongoing or active infection, hydronephrosis, hypertension, diabetes, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and/or the sponsor. Patients with such conditions should be discussed with the Medical Monitor prior to enrollment. All medical conditions must be NCI CTCAE Grade 1 or lower at baseline.

• Unwillingness or inability to comply with requirements of this protocol